Liver
- Persistent Hepatic Steatosis Increases Heart Failure and Mortality Risk
- Advanced Fibrosis, Cirrhosis Rates Elevated in Type 2 Diabetes
- Direct-Acting Antiviral Treatment Rates for HCV Infection are Suboptimal
- Analgesic Use Patterns Differ Among Inpatients With and Without Cirrhosis
- Statins May Prevent Development, Progression of Nonalcoholic Fatty Liver Disease
- Direct-Acting Antiviral Therapy Improves Survival in Chronic Hepatitis C
- Tocilizumab, Sarilumab Associated With Liver Injury Risk in COVID-19 Treatment
- Patients With Alcohol Use Disorder Less Likely to Receive Direct-Acting Antiviral HCV Treatment
- Smartphone-Based Scleral Imaging Can Identify Jaundice in Decompensated Cirrhosis
- Antibiotic Prophylaxis Does Not Prevent Hospital-Acquired Infection
- Liver May Be Reservoir for HIV DNA in Patients With HBV Coinfection on ART
- Significant Liver Damage After Hepatitis C Microelimination Seen in Patients With HIV
Conference Coverage
MORE MEETINGS
Clinical Tools
Powered by
Powered by 
